Stock Chart

NAMS

$32.99 +0.55%
Score: 66.0 BUY
LEAPs: SELL $45
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $45
Premium: $4.44
Expiry: Jan 15, 2027
Target: $48
Score: -27

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $29.96 - $30.86 DOWNTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.65
Vol: 0.83x (vs SPY: 1.3x | vs QQQ: 1.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Key Statistics

Market Cap $4B

This NAMS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track NAMS's price movements with trendlines, gamma walls, and key support/resistance levels.